Breaking News, Collaborations & Alliances

Merus, Ono Pharma Enter New Agreement

For Merus’ Biclonics® technology platform to generate a bispecific antibody that treats autoimmune diseases

Merus N.V. has announced that Ono Pharmaceutical Co. has exercised its option under an agreement executed in April 2014 to enter into a new research and license agreement utilizing Merus’ proprietary Biclonics® technology platform to generate a bispecific antibody that binds to a combination of targets designed for the treatment of autoimmune diseases.     In April 2014, Merus and Ono entered into a research and license agreement to jointly develop bispecific antibody therapies for autoi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters